Biomarker analysis in advanced colorectal cancer patients treated with mFOLFOX6 plus bevacizumab or XELOX plus bevacizumab - Biomarker analysis in advanced colorectal cancer patients treated with mFOLFOX6+bevacizumab or XELOX+bevacizumab

West Japan Oncology Group0 个研究点目标入组 100 人开始时间: 2013年11月29日最近更新: 2023年10月17日

试验速览

暂无简介。

•1. Brain metastasis with symptoms. 2. Massive ascites, pleural effusion or pericardial effusions that need medical treatment. 3. Active another malignancies 4. Non-healing wound (excluding central venous port) 5. Major surgical procedure within 28 days prior to enroll in this study. (Minor surgical procedure within 14 days prior to enroll in this study.) 6. Other serious concomitant disease. a) intestinal obstruction b) History of arterial thromboembolic events such as unstable angina, myocardial infarction, and cerebrovascular accidents within 6 months. c) Clinically significant cardiovascular disease d) Severe pulmonary fibrosis, interstitial pneumonia or COPD on chest XP e) Uncontrollable hypertension f) Uncontrollable diabetes mellitus g) Active peptic ulcer h) Uncontrollable diarrhea i) Hemorrhagic Diathesis j) HIV infection 7. Regular use of corticosteroid. 8. Peripheral neuropathy>=Grade 1 at baseline. 9. Active local or systemic infectious disease. 10. History of serious hypersensitivity. 11. Blood tests positive for HBs antigen. 12. Uncontrollable severe mental disorder. 13. Pregnant or lactating female. 14. Judged inappropriate by the investigators

发起方